Re
Reata Pharma (Biogen)
Plano TXFounded 2002200 employees
Private CapbiotechAcquiredNeurologyNephrology
Platform: Nrf2 FA
Market Cap
N/A
All Drugs
4
Clinical Trials
5
Failed / Terminated
0
FDA Approved
1
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Adagrazasiran | REA-3630 | Approved | 2 | CD3 | CLLPsoriasis | ||
| Capiratamab | REA-6105 | Phase 1 | 1 | Tau | Atopic Derm | ||
| Capisotorasib | REA-7846 | Phase 1 | 1 | CD3 | CKDMDS | ||
| REA-1693 | REA-1693 | Preclinical | 1 | Nectin-4 | NMOSD |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (5)